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Abstract
Implementation of multicenter and/or longitudinal studies requires an effective quality
assurance program to identify trends, data inconsistencies and process variability of
results over time. The Diabetes Control and Complications Trial (DCCT) and the follow-up
Epidemiology of Diabetes Interventions and Complications (EDIC) study represent over 30
years of data collection among a cohort of participants across 27 clinical centers. The qual-
ity assurance plan is overseen by the Data Coordinating Center and is implemented across
the clinical centers and central reading units. Each central unit incorporates specific
DCCT/EDIC quality monitoring activities into their routine quality assurance plan. The
results are reviewed by a data quality assurance committee whose function is to identify
variances in quality that may impact study results from the central units as well as within
and across clinical centers, and to recommend implementation of corrective procedures
when necessary. Over the 30-year period, changes to the methods, equipment, or clinical
procedures have been required to keep procedures current and ensure continued collec-
tion of scientifically valid and clinically relevant results. Pilot testing to compare historic pro-
cesses with contemporary alternatives is performed and comparability is validated prior to
incorporation of new procedures into the study. Details of the quality assurance plan
across and within the clinical and central reading units are described, and quality outcomes
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Introduction
Ensuring high-quality data collection is essential for performing reliable analyses to achieve
meaningful conclusions from the study data. Several factors can impact data quality and com-
pleteness, including the accuracy of instruments and measurement techniques, the standardi-
zation of data collection across clinical centers, and consistency of analysis in the central
reading centers [1–3]. Longitudinal cohort studies face additional challenges that include
advances in technology, changes in the availability of materials and equipment, and staff turn-
over. Therefore, robust quality assurance procedures must be developed and implemented to
minimize potential sources of error during and after data collection.
Several longitudinal studies have described their quality assurance procedures [4–7]. How-
ever, reports on quality assurance practices in large multicenter longitudinal studies, especially
ones that have spanned decades are limited. The Diabetes Control and Complications Trial
(DCCT: 1983–1993) was a multicenter, randomized 10-year clinical trial designed to compare
the effects of intensive vs. conventional diabetes therapy on the development and progression
of microvascular and neuropathic complications in 1,441 participants with type 1 diabetes mel-
litus. The DCCT demonstrated that intensive glycemic control profoundly reduced the early
manifestations of microvascular and neuropathic complications [8]. The Epidemiology of Dia-
betes Interventions and Complications (EDIC: 1994-present) study was initiated as an observa-
tional follow-up of the DCCT cohort to examine the longer-term effects of the DCCT assigned
therapies on microvascular, macrovascular and neuropathic complications [9]. EDIC is cur-
rently in its 22nd year of data collection and is following 94% of the surviving cohort. The pri-
mary aim of this report is to provide an overview of the DCCT/EDIC quality assurance
processes employed over the past 30 years to maintain consistent high-quality data collection.
Methods
Structure of the DCCT/EDIC Study
The DCCT was comprised of 29 clinical centers located in the United States (US) and Canada,
three central reading units and a coordinating center. The clinical centers were responsible for
recruitment, enrollment and protocol implementation activities. Prospective subjects with type
1 diabetes between the ages of 13–39 years with minimal or no microvascular complications
and no macrovascular disease were evaluated during an extensive 4 month screening process.
Eligible subjects (n = 1,441) were randomly assigned to either intensive or conventional ther-
apy. Intensive therapy was designed to achieve near normal glycemia using 3 or more daily
injections of insulin or an insulin pump, with dosing decisions based on frequent daily self-
monitoring of blood glucose. Conventional therapy focused on the absence of hypoglycemia
and hyperglycemia and was consistent with current standard clinical care practices. Staff mem-
bers at the clinical centers were responsible for ongoing medical care and education, and com-
pletion of protocol-mandated evaluations. All biochemical analyses were performed by the
Central Biochemistry Laboratory (CBL: University of Minnesota, Minneapolis MN); stereo-
scopic fundus photographs were graded by the Central Ophthalmologic Reading Center
(CORU: University of Wisconsin, Madison WI); and electrocardiograms (ECGs) were read by
the Central ECG Reading Center (CERC: University of Minnesota, Minneapolis MN). Data
Quality Control DCCT/EDIC
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collection forms were sent from the clinical centers to the Data Coordinating Center (DCC:
George Washington Biostatistics Center, Rockville MD) to be entered into the central database,
and data files from the central units were transmitted and merged into each participant’s cen-
tralized data file. The DCC provided the overarching organization, coordination and support
structure for the study. Ongoing data review based on pre-defined parameters specified in the
protocol identified existing safety concerns and the DCC monitored treatment implementation
and medical outcomes.
Following the DCCT, the participants were invited to enroll in the EDIC longitudinal obser-
vational follow-up study. Two central coordinating centers, each with distinct functions, sup-
port and oversee all of the operational aspects of the EDIC study. The clinical centers are
responsible for direct interface with the study participants and data collection, and the central
reading units provide technical expertise for the evaluation of laboratory samples, fundus pho-
tographs and ECGs (Fig 1). Institutional Review Board (IRB) approval was obtained by each of
the individual clinical centers as well as the Data Coordinating Center. Written informed con-
sent was provided by each of the study participants at the clinical centers. Consent for minor
participants at study screening and randomization was provided by the minor’s parent or legal
guardian, as directed by local institutional guidelines.
Coordinating Centers
Data Coordinating Center. Data management and analytic support for the EDIC study
are provided by the Data Coordinating Center (DCC: George Washington University Biostatis-
tics Center, Rockville MD). The DCC coordinates the development of data collection instru-
ments, designs and maintains a centralized data management system and a secure internal
study website, coordinates the transmission of data from the central reading units, distributes
concise reports of participant results, and develops periodic monitoring reports for oversight
committees and funding agencies. Statisticians at the DCC are responsible for developing ana-
lytic plans, performing analyses for all core data and ancillary studies, and supporting the
development of scientific publications and presentations.
Clinical Coordinating Center. Overall coordination and fiscal management of the clinical
centers is provided by the Clinical Coordinating Center (CCC: Case Western Reserve, Cleve-
land, OH). The CCC supports the clinical aspects of protocol implementation and oversees
staff transitions at the clinical centers. With the addition of ancillary protocols involving new
measurements, the CCC works closely with investigators to standardize equipment and pro-
cesses across the clinical centers. Fiscal responsibilities include maintenance of subcontracts
and budget management oversight at the clinical centers. Through its activities with the clinical
centers, the CCC supports the quality assurance efforts that are overseen by the DCC.
Clinical Centers
Twenty seven of the original 29 clinical centers in the US and Canada participate in the EDIC
Study, and participants from the 2 remaining DCCT clinics continue to participate and are
being followed at a nearby EDIC clinical center. Study personnel at each center include the
principal investigator and study coordinator, with additional administrative, research and/or
nursing support based on participant enrollment and local clinical center resources and prefer-
ences. Standardized processes for the collection of outcome measures are defined in the EDIC
Manual of Operations (MOO) and utilized by all clinical centers. The MOO also defines spe-
cific training and certification activities that are required prior to collection of study data and
provides guidance related to participant communication and study retention [10].
Quality Control DCCT/EDIC
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Central Reading Centers
Central reading centers are responsible for the analysis of biochemical laboratory results, fun-
dus photographs, and ECGs. Additional central reading centers are established to support
ancillary studies that require additional or unique expertise beyond that found within the exist-
ing reading centers. Each reading center has defined quality control systems in place to moni-
tor and evaluate equipment functioning, validate consistency of measurements over time and
across various personnel and systems, and has specified staff training and retraining activities.
Changes in equipment or processes that may affect data quality and integrity are evaluated for
measurement consistency to ensure validity of longitudinal analyses over time. Additionally,
blinded re-reading of a standard set of measures at pre-defined intervals for study procedures,
such as fundus photographs or ECGs, and collection of split-duplicate samples for biochemical
laboratory samples are used to evaluate and track potential differences in instrument character-
istics, personnel behaviors and/or product variations over time. An overview of the various
measures, specimen requirements, collection procedures, testing frequency, as well as the qual-
ity and precision plan is presented in Table 1.
Data Quality Assurance Plan
The EDIC data quality assurance plan relies on the utilization of procedures and processes that
are standardized, reproducible, and measureable over time. Each central reading unit must
ensure uninterrupted, reproducible and comparable data accuracy and reliability over time and
especially whenever equipment or procedural changes are necessary. The individual quality
assurance plans at the DCC, clinical centers, and central reading centers are described.
Data Coordinating Center
The DCC is instrumental in establishing procedures for data quality and adherence and in
developing study monitoring reports for internal and external evaluation. In 2012, the DCC
Fig 1. Data Flow in the DCCT/EDIC Study. The CERC was located at the University of Minnesota,
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transitioned from a paper-based legacy system to a custom built web-based data acquisition
and management system called MIDAS (Multi-modal Integrated Data Acquisition System), a
proprietary system developed by the George Washington Biostatistics Center and used by all
clinical research studies coordinated there. Many aspects of the DCC’s current quality assur-
ance program are integral parts of the MIDAS system, beginning with the development, testing
and implementation of data collection forms. All content for data collection forms and instru-
ments are developed by a sub-committee of study group members and reviewed and finalized
successively by the Data Quality Assurance, Adherence Monitoring, and Executive Commit-
tees. Once approved, the forms are implemented through three sequential databases in
MIDAS: one for form development, one for testing data collection forms, and a third for pro-
duction where real data are collected.










Blood Pressure Resting Systolic,
Diastolic
Quarterly Annually Sitting right arm NO NA
Ankle Brachial Index Not done Biannually Supine bilateral NO NA
Height Height to nearest 0.1
cm
Quarterly Annually 1.0 cmc NO NA
Weight Weight to nearest 0.1
kg
Quarterly Annually 0.2 kgd NO NA





Quarterly Annually Whole Blood YES Split
Duplicate
Creatinine Annually Annually Frozen Serum YES Split
Duplicate




Cholesterol Annually Even randomization
anniversary
Frozen Serum YES Split
Duplicate
Triglycerides Annually Even randomization
anniversary
Frozen Serum YES Split
Duplicate
HDL-Cholesterol Annually Even randomization
anniversary
Frozen Serum YES Split
Duplicate
LDL-Cholesterol Annually Even randomization
anniversary
Frozen Serum YES Split
Duplicate
URINE MEASUREMENTS






















ELECTROCARDIOGRAM Electrocardiogram Annually Annually 12-Lead
Resting
YES Reread
a Data analyzed at the central reading units (e.g. CBL, CORU, CERC);
b EDIC-specific quality assessments
c Height: two measurements within 1 cm; if not, measure twice more
d Weight: two measurements within 0.2 kg; if not, measure twice more
doi:10.1371/journal.pone.0141286.t001
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MIDAS provides on-screen, real-time data validation. Data entry personnel at the clinical
centers are immediately notified while entering a data item if it falls outside a valid range, vio-
lates some other criterion (e.g. skip pattern), or when a required data item is omitted. All data
are checked for discrepancies (within or across forms) nightly and reports are generated in
MIDAS frequently. Reports are sent to the clinical centers to correct or to explain why the data
values are missing or invalid. Quality control includes discrepancy management through bi-
weekly DCC staff meetings to review clinical center responses to data issues. MIDAS maintains
an audit trail of all data modifications throughout the lifetime of the study.
Data security is also incorporated directly into the MIDAS system. Authorized personnel
must be registered and are assigned a level of access based on their responsibilities. All data
entered into the MIDAS system are backed up on a daily basis to ensure data integrity. The
DCC performs a yearly database lock which includes additional data validation and verification
prior to reporting results annually to the EDIC Observational Study Monitoring Board. The
DCC’s data quality assurance plan complies with the standards, policies, and procedures of the
Health Insurance Portability and Accountability Act (HIPAA).
Clinical Centers
Certification Procedures. Individuals performing the procedures to acquire the multiple
outcome measurements are trained, tested, and certified as competent prior to performance of
measurements or collection of data involving study participants. Periodic retraining and certifi-
cation reinforce consistency and standardize the training of new personnel. Once certified, the
individual is assigned a unique identification number which is tracked to ensure that certified
individuals are collecting the appropriate data (Table 2). Additional training and certification
activities are performed prior to implementation of new measurements or approved ancillary
studies to ensure uniformity of measurements and data collection across the clinical centers.
Re-certification is recommended for individuals not involved in the study for 3 or more years
prior to performing any data collection activities.
History and Physical. A standardized history form is used to document specific partici-
pant self-reported outcomes. Designated outcomes require the completion of event-specific
verification forms based on additional medical information obtained from the participant’s
health care providers and/or local healthcare institutions. External medical records document-
ing all cardiovascular events and participant deaths are reviewed and adjudicated by the Mor-
bidity and Mortality Committee, which is comprised of select principal investigators
representing the clinical centers and the ECG central reading unit.
Blood Pressure Measurements. Blood pressure is measured using standardized proce-
dures and equipment at the clinical centers as outlined in the EDIC MOO. Two sitting mea-
surements, taken on the right arm unless contraindicated, are obtained at each participant’s
visit, following 5 minutes at rest and again 2 minutes later. Additionally, dual Doppler blood
pressure measures are performed and the average systolic pressure recorded for bilateral dorsa-
lis pedis, posterior tibial and brachial are used to compute ankle:brachial index. Every four
months, study-wide blood pressure data is reviewed by the Data Quality Assurance (DQA)
committee to assess digit preference, frequency of missing data, as well as measurement means,
ranges, reliability, variability, and frequency of extreme values. Problems and/or trend identifi-
cation guide re-training efforts.
Central Reading Centers
Central Biochemistry Laboratory. Biospecimen collection, processing and shipment
across clinical centers are standardized via protocols defined in the EDIC MOO. Biospecimen
Quality Control DCCT/EDIC
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testing is performed in the Clinical Laboratory Improvement Amendments (CLIA)-certified
and College of American Pathologists (CAP)-inspected CBL. In accordance with CLIA and
CAP, the CBL performs daily quality control testing and participates in external CAP profi-
ciency survey testing for all analytes. External reference materials are tested and monitoring
programs are followed; these include the Centers for Disease Control (CDC) lipid comparabil-
ity program, testing of National Institute of Standards and Technology (NIST) reference mate-
rials for glucose and creatinine measurements, and the National Glycohemoglobin
Standardization Program (NGSP) and International Federation of Clinical Chemistry (IFCC)
monitoring of glycated hemoglobin. Split duplicate samples collected by the clinical centers are
analyzed and the results are compared; these data are reviewed quarterly by the DQA commit-
tee (Table 3).
The quality control plan evaluates the sample management process, from time of collection,
processing and storage at the clinical center, to shipment and eventual sample measurement at
the CBL. Deviations are identified and efforts made to determine the location and cause of the
deviation. This involves re-analysis of the samples in question, communication with the clinical
center about discrepancies related to sample processing, labeling or shipment, and/or tracking
of the results from the CBL to the DCC. Causes of all deviations are documented and commu-
nicated to the clinical centers in an effort to reduce recurrence.
Central Ophthalmologic Reading Center. Bilateral stereoscopic color fundus photo-
graphs were obtained from study participants at baseline and semi-annually through the
DCCT, and during EDIC at baseline and every 4 years based on each participant’s randomiza-
tion anniversary, plus full cohort photos during EDIC years 4 and 10. A standardized photo-
graphic protocol was modified from the 7-Standard Fields protocol of the Early Treatment
Diabetic Retinopathy Study (ETDRS) [13] and clinical sites and equipment were certified by
the ophthalmologic reading center. Until 2011, film images were obtained as 35mm color
slides. Since then, digital images of the fundus have been obtained and graded by the CORU
using methods adapted from the evaluation of film. Each set of images is given a quality score
by reading center technicians. Submissions of only fair or poor quality have the underlying rea-
son for suboptimal quality identified, whether due to technical quality (focus, illumination,
field definition, etc.) or eye-related (cataract, small pupil, vitreous hemorrhage, etc.). Image
quality is compiled for each clinical site; sites with recurrent inadequate performance are coun-
selled by reading center photographers until quality meets acceptable levels.
Fundus photographs are graded by technicians who are trained and certified by the reading
center using light boxes with stereoscopic viewers for film and a modified display and analysis
Table 2. Certification and Standardized Processes in the DCCT/EDIC Study.




Medical history / physical
exam
Completion of data collection form on 2non-study participants X X
Blood pressure Knowledge of study-specific measurement criteria X X
Data entry Training module; entry and submission of “test” data form X X
Shipment of biosamples Shipment of cold and frozen “test” samples X X
Visual acuity Use of study-specific visual acuity techniques; training by local
ophthalmology staff
X X
Ophthalmology exam Submission of curriculum vitae that documents ophthalmology expertise;
knowledge of exam requirements and form completion
X
Electrocardiogram Paper submission of 2 “test” subject ECG’s to CERC; successful digital
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application (IMAGEnet: Topcon Medical Systems, Paramus NJ) with a hand held stereoscopic
viewer for digital images. Diabetic retinopathy is assessed in each field according to the pres-
ence and severity of index lesions (including microaneurysms, hemorrhages, hard exudate, ret-
inal thickening, venous beading, intraretinal microvascular abnormalities, and
neovascularization) according to ETDRS procedures [13]. The evaluation consists of two inde-
pendent gradings for each eye, after which a processor is run that flags eyes with discrepant
evaluations. The grading discrepancies are adjudicated by a third grader. If the grading did not
require adjudication, the first grade is considered the grade of record. If adjudication is indi-
cated, the third grading becomes the grade of record. Eyes that are considered ungradable by
only one of the first two graders are reviewed.
Greater efficiency in quality evaluation was realized through a modification of the earlier
work flow, where every submission was given a technical quality score by a specialized imaging
technician. A process was developed whereby the grader evaluates the quality of the image set.
While the image quality of the vast majority of the submissions is adequate, only those image
sets with suboptimal image quality are given a detailed technical score and receive a more
detailed technical quality evaluation.
Table 3. Methods in the DCCT/EDIC Study.
Procedure Measurement Method or Assay Dates of Use
PHYSICAL EXAM
Blood Pressure Resting Systolic, Diastolic Sitting, right arm reading with sphygmomanometer;
average of 2 measurements
1983-Current
Ankle Brachial Index Average of 2 measurements at each of 6 locations 1994-Current
Height Height to nearest 0.1 cm 2 measurements within 1 cm; if not, measure twice more 1983-Current
Weight Weight to nearest 0.1 kg 2 measurements within 0.2 kg; if not, measure twice more 1983-Current
Waist, Hip Girth Girth to nearest 0.5 cm 2 measurements within 0.5 cm; if not, measure twice more 1994-Current
BLOOD MEASUREMENTS (non-
fasting)
Glycosylated hemoglobin High-performance ion-exchange liquid chromatography 1983-Current
Serum Creatinine Jaffe rate 1983-May 2007
Serum Creatinine Enzymatic method June 2007-Current






Cholesterol Cholesterol oxidase spectrophotometry 1983-Current
Triglycerides Glycerol-blanked glycerol kinase/glycerol oxidase
spectrophotometric
1983-Current
HDL-Cholesterol Magnesium dextran precipitation and cholesterol oxidase
spectrophotometric
1983-Current
LDL-Cholesterol Calculated, Friedewald equation 1983-Current
URINE MEASUREMENTS
Creatinine Clearance Urine Creatinine, 4-hour Jaffe rate 1983-May 2007
Urine Creatinine, 4-hour Enzymatic June 2007-July 2012
Urine Creatinine, random Enzymatic August 2012-Current
Albumin Excretion Urine Albumin, 4-hour Fluorescent immunoassay 1983-July 2012
Urine Albumin, random Immunoturbidimetric August 2012-Current
Albumin Excretion Rate Calculated 1983-July 2012
Albumin-Creatinine Ratio Calculated August 2012-Current
FUNDUS PHOTOGRAPHY Stereoscopic Fundus
Photography
Final ETDRS Grading Scale for Retinopathy and Macular
Edema [11]
1983-Current
ELECTROCARDIOGRAM Electrocardiogram Revised Minnesota Code [12] 1983-Current
doi:10.1371/journal.pone.0141286.t003
Quality Control DCCT/EDIC
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Grading reproducibility is monitored through re-grading of submissions identified by the
DCC. ETDRS retinopathy severity level and other ordinal variables are analyzed using a
weighted Kappa and percentage agreement while continuous variables, such as area of macular
thickening, are analyzed by intra-class correlation, scatter plots and agreement within a speci-
fied limit and reported to the DQA committee [14]. The range of the weighted Kappa statistic
for DR severity by eye was 0.76–0.81 for the last 3 annual exercises, which is consistent with
historical reproducibility [15].
Central ECG Reading Center. Quality control (QC) measures were instituted during the
DCCT and applied unchanged in the EDIC study. Senior staff continuously monitor ECG
quality and identify any procedural errors in ECG acquisition. Lead reversal is particularly
problematic and more common than is generally recognized for the standard resting ECG.
Quality grades assigned to each ECG are used to compile continuous quality trend analysis
data to identify emerging problems, which is particularly important as ECG personnel change
over the duration of study.
A series of quality control (QC) reports are sent regularly to the DCC. The ECG quality
grades are 1, 3, and 5. Grade1 is perfect while grade 3 reflects an increasing amount of artifacts.
ECGs with grade 1 and grade 3 are fully retrievable for study data, whereas grade 5 ECGs (the
poorest quality grade) are generally not suitable for data analysis. Some quality grade 5 ECGs
can be still usable for classification, but are limited particularly with classification of borderline
abnormalities. The overall goal for each clinical center is to ensure the fraction of poor quality
recordings (grade 5) remains below 5% of the total submitted from the clinical center through-
out the study. Declining quality, by individual technicians, clinics or the study as a whole, are
triggers for site investigation and retraining.
Following training and certification of the ECG coders, a quarterly monitoring for inter-and
intra-coders variability is installed. Test library sets of ECGs which have previously been care-
fully coded and verified by senior electrocardiographers are used for blind testing of the visual
coding process. The re-coded data are tabulated no less than quarterly and contingency tables
indicating the frequency of deviations from the standard (off-diagonal elements) are generated.
A Kappa statistic is determined to evaluate coding consistency [14]. Any systematic trends
and/or significant deviations from the standard trigger appropriate corrective action and
retraining of the coding personnel. In addition, a 1% coding daily audit is performed by the
Coding Supervisor. Significant changes in Kappa statistics are carefully examined for the
source of coding change, and to determine if there is a decrement in rule application or change
in coding staff.
To provide repeatability of coding, all EDIC study ECGs are coded by the same coder. All
coded ECGs are reviewed by another coder before being sent for data entry. For the EDIC
study, the codes are checked once again at the time of clinical review reporting, and once again
(fourth time) at the time of monthly reporting to the DCC.
Calibration of machines for a standard gain of 10 mm = 1 mV electrocardiographs are set
invariably. During the reading process, the ECG coders check the calibration of the ECG
machines. Frequent background in specific leads in specific clinics flags machine error espe-
cially if there have been no staff changes in that clinic that may account for the change in
quality.
Role of the Data Quality Assurance Committee
Maintenance of data quality and integrity from collection through dissemination of the results
is the collective responsibility of the entire study group. The DQA committee, comprised of
representatives selected by the Executive committee from the clinical centers, central reading
Quality Control DCCT/EDIC
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units and DCC, is responsible for quality oversight throughout the study. The DQA committee
convenes via teleconference every four months to review study-wide data quality and data
trends over time. The DQA committee evaluates additional monitoring measures for ancillary
studies or new study procedures, and may recommend the implementation of additional qual-
ity control measures to ensure data accuracy and reliability at the clinical centers and/or central
reading units.
Split-duplicate samples are used to monitor reliability and reproducibility of biochemical
laboratory specimens within a defined time period and over time. Mean within specimen coef-
ficient of variation (CV) is the average of the CVs for the sample pairs. The coefficient of reli-
ability (CR) is an estimate of the proportion of the total variability between individual subject
values that is due to differences between the actual values and thus not due to measurement
error. The cumulative CV and CR for biochemical measures since the inception of the EDIC
study in 1994 are presented in Table 4.
Annual re-reads of a pre-defined set of ECGs and fundus photographs assess reproducibility
of results, presence of inter- and intra-reader variation, and/or potential drift in results over
time. Additionally, changes in technical quality of specific measures are identified and clinical
centers are notified to review deviations and investigate potential causes. This feedback mecha-
nism facilitates timely problem identification and implementation of quality improvement
strategies, which together, promote long-term quality improvement (Table 4). Ancillary proce-
dures are tracked and assessed similarly.
Management of Process Change
Advances in technology and changing availability of materials have necessitated changes in the
collection and analysis processes and/or equipment over time in the DCCT/EDIC. Transition
processes are developed to validate the comparability of the results using existing and proposed
technology to ensure reproducibility of results. These processes are described below.
Implementation of Web-based Data Entry
Between 1983 and 2011, the DCCT/EDIC legacy data management system required centralized
data entry by trained and certified keyers at the DCC. With implementation of the MIDAS
data management system, the burden of data entry was transferred from the DCC to each clini-
cal center. Fifty-seven staff members at 27 clinical centers have been trained and certified to
use the web-based data entry system. Three years after the implementation of MIDAS, the
average number of days between the participant’s annual visit and MIDAS data entry fell from
an average of 51 days with the legacy system to 11 days (90% within 25 days).
With the legacy system, paper-based edit reports and participant results were generated
quarterly and mailed to the sites for correction and verification, resulting in a 2–4 month time
lapse from data collection to data reporting. MIDAS web-based data editing and reporting
modules allow for edits to be resolved weekly and for participant reports to be available for
immediate download. The time required for data entry at the clinical centers has been well bal-
anced by the ease of use, rapidity of data editing and availability of time-sensitive data and
reports. Implementation of these changes has resulted in improvements in data quality.
Extensive updates to the secure internal EDIC website also allow for easier access to forms,
protocols, and information sharing, thereby enhancing data quality.
Instrumentation and Assay Changes at the CBL
Over the 30-year history of the study, changes and improvements in laboratory instrumenta-
tion and/or reagents have necessitated changes in the measurement of analytes. To ensure
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accurate and precise laboratory results, new methods and modifications of existing methods
(including instrumentation changes) are validated prior to implementation. Method and/or
instrument evaluation is performed according to the manufacturer’s guidelines when available.
In other instances, guidelines adapted from CAP and the Clinical Laboratory Standards Insti-
tute (CLSI) are followed as appropriate. Such evaluation may include accuracy, precision, sen-
sitivity, specificity, and carry-over analyses. In addition, reportable range, analytical
measurement range, and reference/therapeutic range may be determined.
Two examples of changes in assay methods involve creatinine and cystatin C. Creatinine
measurement using the Jaffe method has been shown to exhibit non-creatinine chromogenic
interference in samples from patients with diabetes [16,17]. Studies were performed to evaluate
comparability and reproducibility of results using current as well as historic stored serum sam-
ples. With comparability established, historic creatinine and creatinine clearance values were
Table 4. Quality Results during the EDIC Study (1994–2014).
BIOCHEMICAL SAMPLES Variability (Coefficient of Variation) Reliability (Coefficient of Reliability)
Serum
Glycosylated hemoglobin 0.48 0.998






Creatininea,b 3.0 / 2.69 0.969 / 0.99
Albumina,b 10.2 / 5.18 0.972 / 0.999
Albumin Excretion Ratea 13.5 0.963
Albumin-Creatinine Ratiob,c 8.91 / 6.24 0.997 / 1.000
Creatinine Clearancea 4.3 0.937
FUNDUS PHOTOGRAPHY
Image Quality (%) Excellent Fair Borderline Unreadable
April 1994–August 2008d (n = 12,724) 58 34 8 1
High Adequate Inadequate











Temporal Drift 2013 (n = 156) 0.8 (0.74, 0.86) 66 91.7 94.9
ELECTROCARDIOGRAM (%) No quality issues Minor technical, readable Unreadable
January 1994–December 2014 (n = 25,761) 93 6 1
a 4-hour timed urine collections (April 1994 –August 2012)
b Single random urine collections (August 2012 –December 2014)
c Single random urine collections (August 2004 –April 2013)
d During the DCCT through 2008 in EDIC, fundus photo quality was assessed using a 4-tier grading system.
e In 2008, the photo image quality control program expanded to include confidence scoring that allowed the graders to indicate their confidence in the
grading of ocular disease as impacted by the quality of the photo set. High—no significant quality issue; Adequate—suboptimal quality interferes with
grading; Inadequate—quality that prevents determination of major disease parameters. (CORU internal white paper: Image Confidence Scores, effective
04 Feb 2008).
f Annual re-read of 100 photo pairs across the spectrum of retinopathy severity performed by the CORU to evaluate reproducibility of scoring over time.
2013 Kappa scores consistent with previous photo re-reads.
doi:10.1371/journal.pone.0141286.t004
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recalculated and reported. The current enzymatic method has less potential for such interfer-
ence. The enzymatic method is calibrated against an IDMS-traceable procedure. Cystatin C
measurement was initially performed using a nephelometric method. However, evidence of
calibrator drift [18] required a change to an immunoturbidimetric method with calibration
traceable to a reference material.
Periodically, procedural changes in the collection methods for biochemical samples are war-
ranted. Recognizing the participant burden of a 4-hour timed urine collection, a pilot study
was conducted to compare albumin excretion rates from the standard 4-hour timed collection
with a single random void [19] to assess the comparability of the two urine collection proce-
dures prior to the study-wide protocol change. Verification of comparability prior to adoption
of the simpler method sustained the continued longitudinal evaluation of renal function over
more than 30 years of follow-up.
Transition from Film to Digital Images
During EDIC, digital fundus camera equipment became more commonplace in EDIC clinical
centers, access to film stock and certified film development was becoming problematic due to
obsolescence, and the quality and resolution of digital fundus images from newer cameras
began to approximate the quality of film images. However, troublesome new artifacts and qual-
ity issues were found in digital retina images, particularly with respect to illumination and
color contrast that was much more variable with digital images than in film. The CORU tested
sets of digital and film images on the same eyes to determine the optimal conditions for grading
digital images to compare to film images with similar sensitivity and reproducibility [20]. As a
minimum standard, fundus camera equipment was required to have a resolution of 3 mega-
pixels and certification submissions had to have good illumination and tonal balance along
with the standard quality attributes carried over from film grading. In addition, a post hoc stan-
dardized illumination and tonal balance optimization process was developed [21] and applied
to all images through a custom software application developed with Dr. Nicola Ferrier, Profes-
sor of Computer Sciences, University of Wisconsin-Madison. Through these processes, the
reproducibility and agreement of grading between digital and film images of the same eyes
became equivalent to historical CORU reproducibility from resampled film image grading.
A pilot study was conducted to compare digital images to film from EDIC clinical centers.
Once quality and comparability were verified, clinical center photographers and equipment
were certified for obtaining digital images. Procedures were modified for digital photography,
however, the same 7 stereoscopic field protocol is used. Quality assessments include artifacts
unique to digital imaging. The reading center grading procedures have adapted for the new dig-
ital work flow and analysis environment, and graders are allowed limited use of digital tools
such as zoom and viewing in the green RGB channel.
Transition to Digital ECG Recording and Electronic Transmission
The EDIC study implemented digital ECG recording using GE MAC 1200 ECG machines (GE,
Milwaukee WI) in late 2014. Unlike non-digital (paper) ECG data collection, the recorded digi-
tal signal can be stored indefinitely without the risk of deterioration of the ECG tracings and
has the ability to automatically record hundreds of ECG waveform measurements that are
logistically impossible to obtain from paper ECGs. The recorded signal is transmitted directly
to the ECG reading center via phone lines which speeds up the reading process with less effort
and cost. All technicians were trained on how to use the new digital ECG machines, and how
to electronically transmit the recorded ECGs to the ECG Reading center.
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Discussion
Data integrity, reliability and reproducibility are important requirements for any research proj-
ect. In the context of multicenter and/or longitudinal studies, an effective monitoring program
that is designed to identify trends, data inconsistencies and process variability and be respon-
sive to temporal technologic changes is essential to ensure validity and comparability of results
over time.
The DCCT was designed to identify the relationship between glycemic control and micro-
vascular complications associated with type 1 diabetes. During the DCCT, clinical centers col-
lected an enormous amount of clinical, laboratory, electrophysiologic and behavioral
information using standardized protocols, procedures and processes. All laboratory samples
were collected and processed by the clinical centers following protocols that defined eligibility
criteria for testing, collection sequences and processing instructions. Upon receipt at the CBL,
samples were batched and analyzed using standardized processes. Similar collection and analy-
sis activities occurred for fundus photographs, ECG’s and other clinical tests. Standardized
data management and defined quality control processes at the DCC enabled identification of
data discrepancies, redundancies, and outliers for various clinical evaluations included in the
protocol (Table 1).
Quality assurance oversight of the DCCT (1983–1993), and subsequently of the EDIC study
(1994—present) has been provided by a named committee (DCCT—Standards and Methods
Committee; EDIC—Data Quality Assurance Committee) that includes representation from the
clinical centers, central reading units and the DCC.
The Standards and Methods Committee in the DCCT was instrumental in developing stan-
dardized clinical methods, reviewing data from the central reading units and providing guid-
ance to the DCC. The committee reviewed quality control parameters, identified
inconsistencies, explored sources of variation, and implemented corrective actions as needed to
ensure data quality and integrity. In the EDIC study, the Data Quality Assurance Committee
continues to provide quality assurance oversight and guide the development of specific quality
control processes for new protocol evaluations. Every 4 months, quality measures are reviewed,
and parameters such as inter- and intra-reader variability (i.e. fundus photos, CT scans,
CMRI), coefficients of reproducibility and reliability of split duplicate laboratory samples, and
re-read reproducibility for annual established datasets (photos, ECGs) are assessed. Variations
are flagged and the degree of variation is evaluated to determine research and/or clinical signifi-
cance acutely and over time. Investigations to determine the source of variability are performed
by assessing the path from collection at the clinical centers through analysis and reporting at
the central units. When indicated, staff re-training is recommended to ensure accuracy and
consistency of data collection processes across all of the clinical centers over time.
Transitions to more contemporary methods for data acquisition result in additional time
commitments and altered roles and responsibilities at the clinical centers, reading centers and
coordinating centers. Additional staff are trained and certification activities are implemented
to prevent or reduce risk of loss of data or to minimize any adverse impact on overall data qual-
ity. Some transitions improve efficiency and timeliness of data reports, others reduce patient
and staff burden during study visits, and yet others ensure the long-term integrity of study data
using electronic data capture and storage. In all cases, the procedural changes implemented to
date have preserved or improved data completeness and quality.
While data integrity and reliability are essential to achieve meaningful research outcomes,
there are practical implications when data results are used to augment the delivery of patient
care. DCCT/EDIC participants have access to their clinical research data, currently over 25–30
+ years. These results, which are provided to the participant following each annual study visit
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and, if requested, to their healthcare provider, may be used to monitor health status, track
changes in health outcomes over time, evaluate the impact of treatments prescribed by the
local healthcare provider and guide clinical decisions that impact the participant’s health.
Ongoing use of these results provides early detection and/or treatment of evolving complica-
tions and data to monitor disease progression. Ongoing clinical use of these results further
underscores the importance of ensuring data quality and comparability of the individual
DCCT/EDIC results over time, and contributes to the remarkable and unprecedented high par-
ticipant retention for over 30 years [22].
Conclusion
An effective quality control program is well-defined, provides a systematic review of processes,
flexibly incorporates additional parameters for new protocol measures, and is supported by a
structure that can recognize and adjust to change. The continued success of the DCCT/EDIC
study is based on the ongoing collection of high quality data. The DCCT/EDIC quality assur-
ance program provides a framework for early identification of process inconsistencies, collec-
tion errors, mechanical variances and personnel differences that may impact the longitudinal
validity and comparability of the data results over time. Furthermore, the program described
here may serve as a resource for the development of quality assurance programs by other long-
term clinical studies.
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